Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 81% · stale
- Computed at
- 2026-10-21T06:32:03.721273+00:00
- Claimed
- 55
- Reported
- 55
- Verified
- 55
- Gap
- 0
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed and verified align
Evidence strength Strong
Decision
What the current evidence supports
Agent-assisted assessment · independently reviewed · 2026-10-21
Ready for specialist consideration within its US-approved adjunctive SMA indication.
- Why
- Controlled evidence supports motor-function benefit, with fracture risk and limited postapproval experience. European authorization remains unresolved following manufacturing-compliance concerns.
- Next
- Assess labeled eligibility, bone health and infusion logistics with the treating specialist; follow longer-term outcomes and European authorization updates.
Constraints
Blockers
- Requires ongoing SMN2-targeted treatment.
- Intravenous treatment every four weeks adds logistical burden.
- Fracture risk requires clinical consideration.
- Long-term effectiveness across the broader labeled population remains uncertain.
- European access depends on manufacturing compliance and authorization.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 11
- Tier 1
- 7
- Tier 2
- 2
- Tier 3
- 2
- Supports
- 5
- Contradicts
- 4
- Context
- 2
- Latest observed
- 2026-09-11
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 4
- 2026-09-21 Reading moved from ready to ready.
- 2026-09-22 Reading moved from ready to ready.
- 2026-10-01 Reading moved from ready to ready.
- 2026-10-01 Reading moved from ready to ready.